Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 6/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | HPGD | P15428 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.34 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2787411 | 0.82 | — | — | |
| SCHEMBL78730 | 0.82 | — | — | |
| SCHEMBL7258049 | 0.82 | MAPT (0.40) | KMT2AMEN1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL2787418 | 0.81 | RXRA (0.32) | KMT2AMEN1HTTLMNAALDH1A1 | |
| SCHEMBL2787212 | 0.81 | — | — | |
| SCHEMBL1673912 | 0.79 | — | — | |
| SCHEMBL10568742 | 0.78 | SMN1; SMN2 (0.56) | KMT2AMEN1SMN1; SMN2HTTL3MBTL1 | |
| SCHEMBL2791758 | 0.77 | — | — | |
| SCHEMBL5064183 | 0.76 | — | — | |
| SCHEMBL78094 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669359-B2 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2014-03-11 | — | — | US | disclosed |
| US-20100065123-A1 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | UNITED STATES DEPARTMENT OF ENERGY | 2010-03-18 | — | — | US | disclosed |
| WO-2008109467-A1 | ELECTRICALLY CONDUCTING PORPHYRIN AND PORPHYRIN-FULLERENE ELECTROPOLYMERS | ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100065123-A1 | Electrically conducting porphyrin and porphyrin-fullerene electropolymers | HMBS, PPOX, SLC40A1 | KMT2A 1802/4885MEN1 599/4885SMN1; SMN2 4321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.